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Mevalonate inhibits acid sphingomyelinase
activity, increases sphingomyelin levels and
inhibits cell proliferation of HepG2 and
Caco-2 cells
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Abstract
Background: Sphingomyelin (SM) and cholesterol are two types of lipid closely related biophysically. Treating the
cells with exogenous sphingomyelinase (SMase) induces trafficking of cholesterol from membrane to intracellular
pools and inhibition of cholesterol synthesis. In the present work, we address a question whether increased
cholesterol synthesis affects hydrolysis of SM by endogenous SMases.
Methods: Both HepG2 and Caco-2 cells were incubated with mevalonate. The SMase activity was determined and
its mRNA examined by qPCR. The cellular levels of cholesterol, SM, and phosphatidylcholine (PC) were determined
and cell proliferation rate assayed.
Results: We found that mevalonate dose-dependently decreased acid but not neutral SMase activity in both
HepG2 and Caco-2 cells with HepG2 cells being more sensitive to mevalonate. Kinetic examination in HepG2 cells
revealed that acid SMase activity was increasing with cell proliferation, and such an increase was reversed by
mevalonate treatment. Acid SMase mRNA was not significantly decreased and Western blot showed signs of
proteolysis of acid SMase by mevalonate. After mevalonate treatment, the levels of cholesterol were significantly
increased associated with increases in SM and PC. The cell growth was retarded by mevalonate and the effect was
more obvious in HepG2 cells than in Caco-2 cells.
Conclusion: Mevalonate can trigger a mechanism to enhance SM levels by inhibition of acid SMase. The effect
may ensure the coordinate changes of SM and cholesterol in the cells. Mevalonate also affects cell growth with
mechanism required further characterization.
Keywords: Mevalonate, Sphingomyelin, Cholesterol, Acid sphingomyelinase, Cell proliferation, Phosphatidylcholine,
HepG2, Caco-2
Introduction
Cholesterol and sphingomyelin (SM) are two important
lipid constituents of mammalian cell membranes and are
also co-localized in lysosomes, endosomes, intestinal
vesicles, plasma lipoproteins, and fat milk globular mem-
brane. The coexisting is due to the strong biophysical in-
teractions between the polar group of SM with the
hydroxyl group of cholesterol [1, 2]. Such an interaction
affects the integrity and permeability of the cell mem-
brane and has been considered to be important for sur-
vival of the cells. Although the existence of lipid rafts in
plasma membrane where the cholesterol, sphingolipids
and protein receptors are tightly packed [3–5] has been
recently challenged by studies employed high-resolution
secondary ion mass spectrometry [6, 7], the fact that
interaction of cholesterol and sphingolipids affects cellu-
lar signaling is essentially not altered. Hydrolysis of SM
has been shown to generate both antiproliferative mole-
cules such as ceramide and sphingosine, and proliferative
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molecules such as sphingosine-1-phosphate (S1P) and
ceramide-1-phosphate (C1P) [8, 9]. Cholesterol can also
interact with membrane proteins and scaffold proteins
affecting signal transduction pathways [7]. In addition,
abnormal metabolism of both cholesterol and SM in
plasma may play important roles in pathogenesis of
atherosclerosis [10]. It is therefore important to under-
stand the regulation of the homeostasis between these
two types of lipid.
Cholesterol and SM can be synthesized in mammalian
cells. The rate-limiting enzyme for cholesterol synthesis
is 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR),
which catalyzes the formation of mevalonate from HMG-
CoA. The mevalonate formed will undergo a mevalonate
pathway resulting in formation of cholesterol [11]. Mevalo-
nate pathway also generates non-sterol products which can
affect gene translation and cell proliferation via mechanism
related to post-transcriptional regulation [11, 12]. The SM
levels are affected by both de novo biosynthesis and degrad-
ation. The serine palmitoyltransferase (SPT) is the rate-
limiting enzyme that triggers the de novo SM synthesis. SM
is degraded mainly by acid and neutral SMases, two types
of ubiquitous enzymes in mammalian cells. Acid SMase
(SMPD1) is a lysosomal enzyme that degrades SM internal-
ized or transported in the intracellular vesicles [13], thus
playing important roles in regulating cellular SM levels. It
can also be transported to the membrane to hydrolyze
membrane bound SM and trigger signal transduction path-
ways [14]. Neutral SMase has multiple forms including
nSMase 1 (SMPD2), nSMase 2 (SMPD3), nSMase 3 (SM
PD4) and MA-nSMase (SMPD5) with different biochemical
properties and cellular locations [15]. The best studied
neutral SMase is nSMase 2 that plays important roles in
SM metabolism, cell signaling, tumorigenesis and bone
homeostasis. The newly identified MA-nSMase may be in-
volved in mitochondria related apoptosis [15]. Liver is an
active organ that synthesizes both cholesterol and SM and
secrets both products into circulation and gut. Liver is also
an organ with higher acid SMase activity compared with
many other organs such as intestine and pancreas [16, 17].
Comparing with cholesterol, diet has less influence on SM
levels in plasma, because digestion of SM in the gut is in-
complete, and sphingosine, the hydrolytic product from
SM, is largely not resynthesized to SM in enterocytes and
not entering the circulation in a decent amount [18, 19].
Because cholesterol and SM are two major lipid constitu-
ents in cell membrane, cells must have dedicate mecha-
nisms to regulate the homeostasis of SM and cholesterol.
Previous studies revealed that the levels of cholesterol in
plasma membrane are affected by the membrane levels of
SM. Treating fibroblasts with exogenous SMase caused a
rapid translocation of cholesterol from membrane to intra-
cellular pools [20–22]. Not only on the trafficking of chol-
esterol, hydrolysis of membrane SM also inhibits synthesis
of cholesterol by inhibiting the activity of HMGR [23].
While previous studies focused mainly on the effect of
changed SM levels on cholesterol homeostasis, fewer stud-
ies pay attention on the potential influence of cellular chol-
esterol on enzymes that hydrolyze SM. The present study
addresses a question whether increased cholesterol synthe-
sis induced by providing exogenous mevalonate can affect
SM and SM hydrolytic enzymes in HepG2 liver cells and
Caco-2 intestinal cells.
Results
Mevalonate reduces acid SMase activity in HepG2 and
Caco2 cells
After incubating HepG2 and Caco-2 cells with mevalonate,
we found that the activities of acid SMase were decreased
(Fig. 1). After 24 h incubation, mevalonate significantly
inhibited acid SMase activity in HepG2 cells in a dose
dependent manner. The inhibitory effect was enhanced
after 48 h incubation, and at this time point 5 mM mevalo-
nate, which did not show positive effect at 24 h incubation,
became effective. Caco-2 cells appeared less sensitive than
HepG2 cells to mevalonate treatment, because 24 h incuba-
tion with mevalonate at the same concentrations did not
show similar effects and longer time incubation was re-
quired for reducing acid SMase activity in this type of cells.
Neutral SMase activities were low and no significant
changes were identified for both cell lines under the same
conditions as above (Table 1).
Kinetic observation of the effect of mevalonate on acid
SMase
To examine the kinetic changes of acid SMase activity in
the presence and absence of mevalonate, HepG2 cells
were incubated with 10 and 20 mM of mevalonate for 8,
24, 48 and 72 hours. The changes of acid SMase were
followed at different time points. The results are shown
in Fig. 2. As can be seen, the acid SMase activity in non-
treated group increased rapidly with the time up to 24 h
when the cells were under rapid proliferation. There-
after, the increase in acid SMase was leveled off and
remained at high levels up to 72 hours. However, in the
presence of mevalonate, the increase tendency of acid
SMase activity was blocked after 8 h and reversed there-
after. Mevalonate at 20 mM was more effective than that
at 10 mM. After 72 h incubation, mevalonate at both
doses suppressed acid SMase activity to the level almost
equal to that at the beginning (0 time).
Changes of acid SMase mRNA and protein after
mevalonate treatment
The changes of acid SMase mRNA in HepG2 cells after
24 h incubation was determined by real time PCR.
Although both 10 mM and 20 mM mevalonate inhibited
acid SMase activity, reduction of acid SMase mRNA,
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about 20 %, was only found in the cells treated with
20 mM mevalonate (Fig. 3). However the statistical
significance was not reached and the P value was 0.061
as compared with the non-treated cells. Western blot for
acid SMase did not show significant changes of the
enzyme protein induced by either 10 or 20 mM mevalo-
nate (Fig. 3). However, in all mevalonate treated sam-
ples there was a faint band below the acid SMase
band, which might be a proteolytic product derived
from acid SMase.
Increased contents of cholesterol, sphingomyelin and
phosphatidylcholine by mevalonate
To evaluate whether mevalonate changes the metabol-
ism of cholesterol and SM, the contents of cholesterol,
SM and PC in HepG2 cells were determined. As shown
in Fig. 4, after 24 h incubation, 10 and 20 mM mevalo-
nate increased cellular cholesterol levels by about 46 %
and 175 %, respectively (left panel). Increase in SM con-
tents (middle panel) was also demonstrated but statis-
tical significance was only found for 20 mM mevalonate
treatment. Mevalonate at this concentration also signifi-
cantly increased the PC levels in the cells.
Mevalonate inhibits cell growth in both HepG2 and Caco-
2 cells
Since we found an increase of acid SMase in control
cells with cell growth (Fig. 2), we further examined
whether mevalonate treatment may affect cell prolifera-
tion. We treated both HepG2 and Caco-2 cells with
mevalonate for 48 h, since at this time point, mevalonate
was effective in inhibition of acid SMase in both cell
lines (Fig. 1). We found that cell proliferation in HepG2
and Caco-2 cells was dose-dependently decreased. The
Caco-2 24h





























































































Fig. 1 Dose dependent effects of mevalonate on acid SMase activity in HepG2 and Caco2 cells. The cells were incubated with mevalonate at
different concentrations for 24 and 48 h. The acid SMase activity in the cell-free extracts was determined using choline labeled 14C-SM as substrate.
The activity was adjusted to protein levels in the sample and expressed as percentage of the control (0 concentration of mevalonate). Results are
means ± SD obtained from triple culture wells in three separate experiments. **p < 0.01, ***p < 0.005 compared with the control
Table 1 Changes of neutral SMase activity (pmol/h/mg protein)






0 5 10 20
Caco-
2
24 100 ± 11.9 103.1 ± 26.5 107.3 ± 10.0 97.1 ± 30.7
48 100 ± 14.9 108.0 ± 7.9 88.5 ± 17.8 92.7 ± 12.5
HepG2 24 122.4 ± 16.5 135.1 ± 23.8 118.9 ± 13.2 146.3 ± 39.7
48 129.8 ± 8.5 129.6 ± 11.4 121.5 ± 7.9 125.1 ± 10.4
The cells were treated with mevalonate for 24 and 48 h. The cell lysates were
prepared and overall neutral SMase activities in the supernatant were
determined. Results are expressed as means ± SD obtained from triple samples
for each concentration in separate three experiments
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inhibition is more potent for HepG2 cells than for Caco-
2 cells (Fig. 5).
Discussion
The interaction of cholesterol and SM has been an inter-
esting research field for decades. Previous studies mainly
focused on the effect of changed SM levels on choles-
terol homeostasis, such as cholesterol trafficking and
synthesis [1, 20, 22]. In the present study we address a
question from the opposite direction, i.e. whether
cholesterol synthesis influences SM levels via affecting
SMase activity. The experiment was performed by treat-
ing the cells with mevalonate, the key molecule leading
to cholesterol synthesis. We found that mevalonate at
concentrations increased cholesterol levels, significantly
inhibited acid SMase activity and increased intracellular
SM levels in the cells. The effect was dose-dependent in
both liver and intestinal cells. However the liver cells
demonstrated higher sensitivity than intestinal cells, which
supports the fact that mevalonate pathway is much more
active in the liver than in the intestine [24], and liver has
higher acid SMase activity than the intestine [16].
In general, increased SM levels can result from de-
creased degradation or increased synthesis. At least 3
types of enzymes can hydrolyze SM in human liver and
intestine, i.e. the acid SMase, neutral SMases [13] and
ENPP7 (also called alkaline SMase previously) [25]. In
the present study, the overall activities of neutral SMases
in the cell free lysates after mevalonate treatment for 24
and 48 h were not significantly changed, which, in our
opinion, don’t supports a critical role of neutral SMases
in the changed SM after mevalonate treatment. Due to
the negative results, we did not further address a ques-
tion whether different types of neutral SMase at different
time points could be altered by mevalonate. In addition,
ENPP7, although highly expressed in the intestine and
human liver [26], is also unlikely responsible for the
changes of SM induced by mevalonate, because in
HepG2 cells ENPP7 is inactively mutant [27], and in
Caco2 cells it is only expressed in polarized cells not
monolayer cells [28]. The significant dose dependent
and time-dependent reductions of acid SMase caused by
mevalonate indicate that it is acid SMase that is respon-
sible for the increased SM in the cells. Although SM
levels can also be affected by de novo synthesis, previous
studies have shown that the syntheses of SM and choles-
terol are independent. Neither inhibiting cholesterol



































Fig. 2 Kinetic changes of acid SMase in HepG2 cells in the absence
and presence of mevalonate. The cells were subcultured in different
wells for different time point examinations. One day after subculture,
mevalonates at 0, 10 and 20 mM were added to the wells followed
by incubation for 8, 24, 48 and 72 h. The acid SMase activities were
determined at different time points. Results are means ± SD from triple
wells for each time points in separated three experiments. **p < 0.01,





























Fig. 3 Changes of acid SMase mRNA (upper panel) and Western
blot for acid SMase protein (lower panel) in HepG2 cells. The cells
were incubated with mevalonate at different concentrations for
24 h. The total RNA was extracted and cDNA synthesized. QPCR was
performed on Bio-Rad iCycler system. The results were normalized
with the levels of the housekeeping gene (GAPDH) and expressed
as ratio of the control. The data are expressed as means ± SD obtained
from duplicate culture wells in three separate experiments. The
Western blot (lower panel) for acid SMase was performed in HepG2
cells incubated with mevalonate at concentrations indicated for 24 h.
No statistical significance was identified
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biosynthesis by statins nor enhancing cholesterol biosyn-
thesis by mevalonate has effect on SM biosynthesis [29].
Cholesterol itself did not affect SPT activity [30].
The reduced acid SMase activity by mevalonate ap-
pears occurring mainly at post-translational levels. Al-
though qPCR showed a mild reduction of acid SMase
mRNA by 20 % after incubation with the highest con-
centration of mevalonate, the statistical significance was
not reached. In addition, the Western blot did not reveal
visible changes of acid SMase proteins. However, it
might be worthwhile pointing out that Western blot
showed an additional faint band below the major acid
SMase band in all mevalonate treated samples but not in
nontreated samples. This phenomenon may indicate a
proteolytic action on acid SMase induced by mevalonate.
It has been shown that post-translational modifications
including glycosylation, phosphorylation, and proteolysis
are important steps affecting acid SMase activity [14, 31].
In addition, mevalonate pathway generates both sterol and
non-sterol products. The non-sterol products, which are
mainly derivatives of isopenoids, have been shown to be
able to interact with proteins [8, 9]. Of interest, we previ-
ously showed that triterpenoids such as ursolic acid and
boswellic acid, which are natural sterols chemically de-
rived from isopenoid, can affect acid SMase activity at
post-translational levels [32, 33]. Further studies are ne-
cessary to characterize the underlying mechanisms leading
to the decreased acid SMase activity triggered by mevalo-
nate. In addition, whether the reduced acid SMase activity
by mevalonate is a consequence of translocation of the
enzyme is also a question requiring further investigation.
Many studies have shown that cells can regulate the
content of SM and cholesterol in a delicate coordinate
manner. Those studies mainly focus on the effects of
changed cellular SM on cholesterol synthesis and traf-
ficking [20, 29]. Our results cast a new insight that the












































































Fig. 4 Quantification of SM, PC and cholesterol in the cells after mevalonate treatment. For SM and PC assay, HepG2 cells were first incubated
with 3H-choline chloride to label both SM and PC for 48 h. After washing out the excess 3H-choline chloride, the cells were incubated with
mevalonate for 24 h. The lipids were extracted and analyzed by TLC. The SM and PC bands were scraped according to the standards and the
radioactivity measured by liquid scintillation. The cholesterol was measured by a commercial kit from Cayman. Results are means ± SD from
duplicate culture wells in three separated experiments. * < 0.05, **p < 0.01 compared with nontreated cells
Caco-2















































Fig. 5 Cell proliferation after mevalonate treatment. Both HepG2
and Caco-2 cells were incubated with mevalonate for 48 h. The cell
proliferation was determined by a kit from Trevigen, which was
based on MTT reagent. Results are means ± SD from triple cultured
wells in three separate experiments and expressed as percentage of
the control. ***P < 0.005 compared with control
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direction, i.e. changed cholesterol synthesis also affects
hydrolysis of SM through modifying acid SMase activity.
The coordinate increase in cholesterol and SM may have
clinical implications, as liver has important impact on
the levels of both plasma LDL cholesterol and SM, both
are risk factors in pathogenesis of atherosclerosis [10]. In
addition, very recently, a cohort study shows that long
term statin treatment increases risk of type-2 diabetes
[34]. We previously showed that mevastatin could in-
crease acid SMase in HepG2 cells [35]. The effect could
increase the formation of ceramide that can induce insu-
lin resistance through affecting protein kinase B pathway
[36]. Our study thus may also have implications in
pathogenesis of type-2 diabetes. Besides the changes of
SM, we also found increased PC after mevalonate treat-
ment. PC interacts with cholesterol similarly as SM but
with lower affinity [37]. Increasing of PC by mevalonate
may indicate the existence of a similar regulatory mech-
anism between cholesterol and PC. The mechanism
underlying the increased PC levels after mevalonate treat-
ment was not explored in the present study. Future stud-
ies should examine the changes of enzymes responsible
for PC hydrolysis such as PC-specific phospholipase C,
phospholipase D, and those involved in PC synthesis.
Finally we found that the activity of acid SMase was
increasing with time in non-treated HepG2 cells and the
increase was most obvious at the early stage of the cells
after subculture, when the cells are rapidly proliferating.
The results may indicate essential roles of acid SMase in
cell proliferation at certain stages. In agreement with the
hypothesis, mevalonate inhibited cell growth in both
HepG2 and Caco-2 cells, with HepG2 cells being more
sensitive than Caco-2 cells. We previously found that
boswellic acid, a triterpenoid also inhibited Caco-2 cell
proliferation associated with reduced acid SMase activity
[32]. Since what the kit measured is the total number of
living cells, the results did not provide information for
the mechanism involved. Further comprehensive studies
are required to characterize the underlying pathways
related to cell proliferation and apoptosis. Of interest is
the previous finding that statins, the drugs that inhibit
HMGR, inhibited cell proliferation and induced apop-
tosis [38]. Future studies are required to clarify the
discrepancy between the effects of statins and mevalo-
nate on cell proliferation by detailed quantification of
SM metabolites such as S1P, C1P and signals affected by
statins. As pointed by others, some pleiotropic effects of
statins may not be linked to its effects on cholesterol
synthesis [38].
Conclusion
The study reveals a novel regulatory mechanism between
cholesterol synthesis and SM hydrolysis exerted by acid
SMase. This type of regulation might be important in
ensuring the coordinate changes of cholesterol and SM in




HepG2 and Caco-2 cells were purchased from American
Tissue Culture Collection. Mevalonate, antihuman acid
SMase, anti β-actin, standard SM, PC, and cholesterol
were purchased from Sigma Co (Stockholm, Sweden).
Choline labeled SM (C14-SM) was prepared by Astra
Zeneca (Lund, Sweden). 3H-labeled choline chloride was
purchased from American Radiolabeled Chemicals Inc.
(Malmö, Sweden). Primers for acid SMase and internal
control gene (GAPDH) used in qPCR were synthesized
by DNA Technology A/S (Risskov, Denmark) and the
sequences have been described previously [32]. The
MTT Cell Proliferation Assay (MTT-CPA) kit was pur-
chased from Trevigen (Gaithersburg, USA). The Choles-
terol Quantification kit and cDNA Synthesis kit for qPCR
analysis were purchased from Cayman (Ann Arbor, USA)
and Fermentas (Stockholm, Sweden), respectively.
Cell Culture
HepG2 and Caco-2 cells were cultured in monolayer in
RPMI-1640 medium and DMEM medium, respectively,
containing 4.5 μg/l glucose, 2 mM glutamine, 10 % heat
inactivated FBS, 100 IU/ml penicillin and 10 μg/ml
streptomycin. Mevalonate was dissolved in the culture
medium as a stock and added in the cell culture medium
to final concentrations examined. In the control group,
only the culture medium was added. After incubation,
the cells were scraped, lysed and sonicated as described
[32]. After centrifugation at 10000 g at 4 °C for 10 min,
the activities of SMases in the homogenate were deter-
mined. For kinetic studies, one day after the subculture,
the cells were treated with mevalonate for 8, 24, 48 and
72 h and the acid SMase activities were determined. The
changes of the activity after mevalonate treatment were
expressed as percentage of the values before mevalonate
treatment (0 time value).
SMase assay
The SMase activity was assayed as described before [39].
In brief, for acid SMase assay, 5 μl of sample was added
in 95 μl 50 mM Tri-maleate buffer pH 5.0 containing
0.15 M NaCl, 0.12 % Triton ×100, and 80 pmol 14C-SM.
After incubation at 37 °C for 30 min, the reaction was
stopped by adding 0.4 ml of chloroform/methanol
(2:1 v/v) followed by centrifugation shortly. After phase
partition, the radioactivity in the upper phase containing
cleaved phosphocholine was determined by liquid scintilla-
tion. The neutral SMase activity was assayed similarly but
in 50 mM Tris–HCl buffer, containing 2 mM Mg2+, pH 7.4
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[39, 40]. The activity was adjusted with the protein levels in
the homogenate and expressed as percentage of the values
in control group.
Real time PCR for acid SMase mRNA and Western blot for
acid SMase protein
The total RNA was extracted by TRIzol and cDNA was
synthesized by a cDNA Synthesis kit for RT-PCR pur-
chased from Fermentas. QPCR was performed in 20 μl
volume containing 10 μl SYBR Green Supermix from
Bio-Rad, cDNA samples, and primers on Bio-Rad iCy-
cler system. The qPCR was programmed as 40 cycles of
95 °C for 15 s and 65 °C for 30 s. The melting curve was
analyzed to confirm the specificity of the product ampli-
fied. The threshold (Cr) was analyzed by iQTM Optical
System Software (Bio-Rad). The results were normalized
with the levels of the housekeeping gene GAPDH. The
Western blot was performed as described previously
[32] . In brief, HepG2 cells were treated with mevalonate
for 24 h and 50 mg proteins in cell lysate were subjected
to 7.5 % SDS PAGE. The proteins were transferred to
nitrocellulose membrane and blocked with 5 % non-fat
dry milk. The membrane was then probed with antihu-
man acid SMase antibody (1:200) and then with second
antibody (1:5000) conjugated with horseradish peroxid-
ase. The specific acid SMase bands were identified by
ECL reagents and visualized on Fuji Image. The mem-
brane was then striped and re-probed with antibody
against β-actin as a loading control.
SM, PC and cholesterol assays
The changes of cellular levels of SM and PC were exam-
ined as previously reported [25]. In brief, the cells were
first incubated with 3H-choline chloride (0.5 μCi/ml)
to label the cellular SM and PC for 48 h and the ex-
cess of 3H-choline chloride was washed out thereafter.
The cells were then incubated with mevalonate for
24 h. The total lipids in the homogenates of the cells
were extracted according to Bligh and Dyer [41] and
separated by TLC together with authentic standard
SM and PC. The plate was developed by chloroform/
methanol/ammonium hydroxide (65/25/4 v/v/v). The
SM and PC bands were scraped according to the pos-
ition of standards and the radio activities in SM and
PC bands were measured by liquid scintillation. To
examine the changes of cholesterol, the cells after
mevalonate treatment were sonicated in isopropyl al-
cohol followed by centrifugation at 8000 g for 10 min.
The cholesterol in the supernatant was assayed by a
kit from Cayman according to the instructions of the
company. The protein levels of the homogenates were
determined and the levels of SM, PC and cholesterol
were normalized with the protein contents in the sam-
ples and expressed as % of the controls.
Cell proliferation assay
The cell proliferation was assay by MTT Cell Prolifera-
tion Assay (MTT-CPA) kit from Trevigen. The method
is based on the ability of the cells to hydrolyze tetrazo-
lium and generate purple formazan that can be quanti-
tated spectroscopically at 595 nm on a microplate reader
(Bio-Rad Model 680). The results reflect the total num-
ber of living cells. The determination procedure followed
the instructions of the kit.
Statistical analysis
The experiments were conducted in triple culture wells
in 3 separate experiments. The results are presented as
means ± SD, and analyzed by one way ANOVA followed
by Dunnett’s test to compare the results in treated group
with that in control group. P < 0.05 is considered to be
statistically significant.
Abbreviation
C1P: Ceramide-1-phosphate; HMGR: 3-hydroxy-3-methyl-glutaryl-CoA
reductase; NPP7: Nucleotide pyrophosphatase phosphodiesterase 7;
PC: Phosphatidylcholine; S1P: Sphingosine-1-phosphate; SM: Sphingomyelin;
SMase: Sphingomyelinase; nSMase: Neutral SMase; SPT: Serine
palmitoyltransferase.
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